This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ran, S. Articles by Thorpe, P. E. Search for Related Content PubMed PubMed Citation Articles by Ran, S. Articles by Thorpe, P. E.

Increased Exposure of Anionic Phospholipids on the Surface of Tumor Blood Vessels¹

Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8594, and the Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9041

Anionic phospholipids are largely absent from the external leaflet of the plasma membrane of mammalian cells under normal conditions. Exposure of phosphatidylserine on the cell surface occurs during apoptosis, necrosis, cell injury, cell activation, and malignant transformation. In the present study, we determined whether anionic phospholipids become exposed on tumor vasculature. A monoclonal antibody, 9D2, which specifically recognizes anionic phospholipids, was injected into mice bearing a variety of orthotopic or ectopic tumors. Other mice received annexin V, a natural ligand that binds to anionic phospholipids. Both 9D2 and annexin V specifically localized to vascular endothelium in all of the tumors, and also to tumor cells in and around regions of necrosis. Between 15 and 40% of endothelial cells in tumor vessels were stained. No localization was detected on normal endothelium. Various factors and tumor-associated conditions known to be present in the tumor microenvironment were examined for their ability to cause exposure of anionic phospholipids in cultured endothelial cells, as judged by 9D2 and annexin V binding. Hypoxia/reoxygenation, acidity, thrombin, and inflammatory cytokines all induced exposure of anionic phospholipids. Hydrogen peroxide was also a strong inducer. Combined treatment with inflammatory cytokines and hypoxia/reoxygenation had greater than additive effects. Possibly, injury and activation of tumor endothelium by cytokines and reactive oxygen species induce exposure of anionic phospholipids, most likely phosphatidylserine. Anionic phospholipids on tumor vessels could potentially provide markers for tumor vessel targeting and imaging.

This article has been cited by other articles:

				A. Makovitzki, A. Fink, and Y. Shai Suppression of Human Solid Tumor Growth in Mice by Intratumor and Systemic Inoculation of Histidine-Rich and pH-Dependent Host Defense-like Lytic Peptides Cancer Res., April 15, 2009; 69(8): 3458 - 3463. [Abstract] [Full Text] [PDF]

				F. G. Blankenberg In Vivo Detection of Apoptosis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 81S - 95S. [Abstract] [Full Text] [PDF]

				M. Jennewein, M. A. Lewis, D. Zhao, E. Tsyganov, N. Slavine, J. He, L. Watkins, V. D. Kodibagkar, S. O'Kelly, P. Kulkarni, et al. Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine Clin. Cancer Res., March 1, 2008; 14(5): 1377 - 1385. [Abstract] [Full Text] [PDF]

				J.-N. Rybak, C. Roesli, M. Kaspar, A. Villa, and D. Neri The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases Cancer Res., November 15, 2007; 67(22): 10948 - 10957. [Abstract] [Full Text] [PDF]

				J. He, T. A. Luster, and P. E. Thorpe Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids Clin. Cancer Res., September 1, 2007; 13(17): 5211 - 5218. [Abstract] [Full Text] [PDF]

				J. S. Mader, D. Smyth, J. Marshall, and D. W. Hoskin Bovine Lactoferricin Inhibits Basic Fibroblast Growth Factor- and Vascular Endothelial Growth Factor165-Induced Angiogenesis by Competing for Heparin-Like Binding Sites on Endothelial Cells Am. J. Pathol., November 1, 2006; 169(5): 1753 - 1766. [Abstract] [Full Text] [PDF]

				T. A. Luster, J. He, X. Huang, S. N. Maiti, A. J. Schroit, P. G. de Groot, and P. E. Thorpe Plasma Protein beta-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells J. Biol. Chem., October 6, 2006; 281(40): 29863 - 29871. [Abstract] [Full Text] [PDF]

				X. Huang, W.-Q. Ding, J. L. Vaught, R. F. Wolf, J. H. Morrissey, R. G. Harrison, and S. E. Lind A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties Blood, February 1, 2006; 107(3): 980 - 986. [Abstract] [Full Text] [PDF]

				H. H. Boersma, B. L.J.H. Kietselaer, L. M.L. Stolk, A. Bennaghmouch, L. Hofstra, J. Narula, G. A.K. Heidendal, and C. P.M. Reutelingsperger Past, Present, and Future of Annexin A5: From Protein Discovery to Clinical Applications J. Nucl. Med., December 1, 2005; 46(12): 2035 - 2050. [Abstract] [Full Text] [PDF]

				T. H. Barker, G. Baneyx, M. Cardo-Vila, G. A. Workman, M. Weaver, P. M. Menon, S. Dedhar, S. A. Rempel, W. Arap, R. Pasqualini, et al. SPARC Regulates Extracellular Matrix Organization through Its Modulation of Integrin-linked Kinase Activity J. Biol. Chem., October 28, 2005; 280(43): 36483 - 36493. [Abstract] [Full Text] [PDF]

				X. Huang, M. Bennett, and P. E. Thorpe A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice Cancer Res., May 15, 2005; 65(10): 4408 - 4416. [Abstract] [Full Text] [PDF]

				H.-H. Chen, C. P. Vicente, L. He, D. M. Tollefsen, and T.-C. Wun Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants Blood, May 15, 2005; 105(10): 3902 - 3909. [Abstract] [Full Text] [PDF]

				S. Ran, J. He, X. Huang, M. Soares, D. Scothorn, and P. E. Thorpe Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice Clin. Cancer Res., February 15, 2005; 11(4): 1551 - 1562. [Abstract] [Full Text] [PDF]

				P. E. Thorpe Vascular Targeting Agents as Cancer Therapeutics Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427. [Abstract] [Full Text] [PDF]

				J. Philipp, A. Dienst, M. Unruh, A. Wagener, A. Grunow, A. Engert, J. W.U. Fries, and C. Gottstein Soluble Tissue Factor Induces Coagulation on Tumor Endothelial Cells In Vivo if Coadministered With Low-Dose Lipopolysaccharides Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 905 - 910. [Abstract] [Full Text] [PDF]